Trial Profile

AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis.

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 20 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atorvastatin (Primary) ; Choline fenofibrate (Primary)
Indications Atherosclerosis
Focus Therapeutic Use
Acronyms AFRICA

Most Recent Events

18 Dec 2024 Status changed to withdrawn prior to enrolment.
16 Jun 2011 Additional trial investigator identified as reported by ClinicalTrials.gov.
16 Jun 2011 Planned end date changed from 1 Nov 2010 to 1 Nov 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com